Pyrojas

Executive Summary

Pyrojas is a San Diego-based biotechnology company developing precision immunotherapies to achieve durable control of cancer. Founded in 2016, the company is backed by the National Cancer Institute, Bristol Myers Squibb, and venture capital, and is guided by a world-class team including Nobel Laureate Dr. James Allison. Currently in the pre-clinical stage, Pyrojas focuses on innovative immune therapies that aim to overcome resistance mechanisms and provide long-lasting responses in patients. The company's platform leverages deep immunological insights and has the potential to address multiple tumor types. While no specific pipeline programs have been disclosed, Pyrojas' strong scientific foundation and high-profile support position it as a promising player in the immunotherapy space. The company is private and has not yet reported total funding or valuation.

Upcoming Catalysts (preview)

• Q4 2026IND submission for lead candidate70% success
• Q2 2027Series B or C financing round60% success
• Q2 2026Preclinical data presentation at major conference80% success